Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

158.62 +0.59 (+0.37%)
Streaming Delayed Price Updated: 11:15 AM EDT, Aug 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,955,836
Open 158.50
Bid (Size) 158.60 (600)
Ask (Size) 158.64 (100)
Prev. Close 158.03
Today's Range 156.79 - 159.18
52wk Range 84.81 - 165.71
Shares Outstanding 541,500
Dividend Yield 0.17%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond? ↗
XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% dividend. 
Via The Motley Fool
Topics ETFs
News headline image
Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI? ↗
XBI surged 76% in one year but carries triple the expense ratio and far steeper downside risk. Which fund matches your risk appetite? 
Via The Motley Fool
Topics ETFs

Performance

YTD
+30.5%
+30.5%
1 Month
+2.1%
+2.1%
3 Month
+17.7%
+17.7%
6 Month
+25.8%
+25.8%
1 Year
+86.3%
+86.3%

More News

Read More
News headline image
Here's How Much $100 Invested In State Street SPDR S&P Biotech ETF 20 Years Ago Would Be Worth Today ↗
Via Benzinga
Topics ETFs Stocks
News headline image
Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026? ↗
Via The Motley Fool
Topics ETFs
News headline image
Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best? ↗
Via The Motley Fool
Topics ETFs
News headline image
The Best Biotech Stocks to Buy in 2026 ↗
Via The Motley Fool
Topics ETFs
News headline image
Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors? ↗
Via The Motley Fool
Topics ETFs
News headline image
3 Longevity ETFs to Buy and Hold (and Hold) ↗
Via MarketBeat
Topics Artificial Intelligence ETFs
News headline image
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech ↗
Via The Motley Fool
Topics ETFs
News headline image
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost ↗
Via The Motley Fool
Topics ETFs
News headline image
2 Ways to Play the Big Pharma Patent Cliff ↗
Via MarketBeat
Topics ETFs Intellectual Property
News headline image
Small Caps Under Siege: Russell 2000 Enters Correction as Yields Surge
Via MarketMinute
Topics Bonds ETFs Economy
News headline image
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins ↗
Via Stocktwits
Topics ETFs
News headline image
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)
Via Finterra
Topics ETFs Intellectual Property
News headline image
Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? ↗
Via Stocktwits
Topics ETFs
News headline image
QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit ↗
Via Stocktwits
News headline image
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure ↗
Via Stocktwits
Topics Initial Public Offering
News headline image
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗
Via Stocktwits
News headline image
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗
Via Stocktwits
News headline image
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗
Via Stocktwits
News headline image
Why Did CRMD Stock Tumble Over 11% Today? ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Why Did BTAI Stock Surge 20% In Pre-Market Today? ↗
Via Stocktwits
News headline image
Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
DAWN Shares Rally On Buyout Speculation But Retail Warns A Deal Might Not Materialise ↗
Via Stocktwits
Topics Economy

Frequently Asked Questions

Is State Street SPDR S&P Biotech ETF publicly traded?
Yes, State Street SPDR S&P Biotech ETF is publicly traded.
What exchange does State Street SPDR S&P Biotech ETF trade on?
State Street SPDR S&P Biotech ETF trades on the New York Stock Exchange
What is the ticker symbol for State Street SPDR S&P Biotech ETF?
The ticker symbol for State Street SPDR S&P Biotech ETF is XBI on the New York Stock Exchange
What is the current price of State Street SPDR S&P Biotech ETF?
The current price of State Street SPDR S&P Biotech ETF is 158.62
When was State Street SPDR S&P Biotech ETF last traded?
The last trade of State Street SPDR S&P Biotech ETF was at 08/11/26 11:15 AM ET
What is the market capitalization of State Street SPDR S&P Biotech ETF?
The market capitalization of State Street SPDR S&P Biotech ETF is 85.89M
How many shares of State Street SPDR S&P Biotech ETF are outstanding?
State Street SPDR S&P Biotech ETF has 86M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.